Clinical Trials Logo

Obesity, Abdominal clinical trials

View clinical trials related to Obesity, Abdominal.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06057207 Recruiting - Surgery Clinical Trials

Perioperative Adiponectin and Postoperative Inflammatory Response After Major Abdominal Surgery

ADIPOS
Start date: July 27, 2023
Phase:
Study type: Observational

Surgical stress after major abdominal surgery in perioperative period causes neuroendocrine, metabolic and imunologic changes in organism with production of proinfflamatory citokines and results with appearance of systemic infflammmatory response syndrome (SIRS). Dysregulated and overrated SIRS in early postoperative period can lead to complications with additional comorbidities, longer hospital stay and poorer outcome. A low grade chronic infflammatory state in obesity and hypoadiponectinemia can enable the cytokine storm and exaggerated /dysregulated SIRS in obese patients after surgery. Obesity according to this knowledge presents independent risk factor for developing more severe systemic infflamatory response syndrome in early postoperative period after major abdominal surgery. Hypothesis: Lower blood adiponectin levels are associated with higher systemic infflamatory response in patients after major abdominal surgery. Major aim of this study is to investigate correlation between perioperative blood levels of adiponectin and markers of systemic infflamation in patients after major abdominal surgery.

NCT ID: NCT06024018 Recruiting - Central Obesity Clinical Trials

Effect of High Intensity Electromagnetic Body Shaping on Profile of Metabolism in Obese Men

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

high intensity focused electromagnetic technology's secondary effects are observed in the fat (adipose). within 8 h of a treatment session, apoptotic levels in adipose increased 91.7%.8 In addition, after the application of the high intensity electromagnetic technique, there is an increase in the rapid release of free fatty acids, so it can be used in weight loss

NCT ID: NCT05972109 Recruiting - Insulin Sensitivity Clinical Trials

Metabolic Health Improvement Program: Effects of a Workplace Sugary Beverages Sales Ban and Motivational Counseling

MHIP
Start date: August 1, 2023
Phase: N/A
Study type: Interventional

The purpose of the study is to test the impact of a multilevel workplace intervention (hospital-wide sales ban on sugar-sweetened beverages (SSBs) and individual-level brief counseling) on employee health.

NCT ID: NCT05966727 Recruiting - Diabetes Clinical Trials

Exploratory Evaluation of the Effect of Cholestyramine on Serum Levels of POPs in Obese Female Patients

OBESE
Start date: March 31, 2024
Phase: N/A
Study type: Interventional

Environmental endocrine disruptors (EDCs) represent a major problem for human health.Some PEEs can accumulate in the fatty tissue of the human body thanks to their lipophilic nature, and are known as persistent organic pollutants (POPs). To assess the benefit of cholestyramine treatment on POPs blood levels in obese patients of childbearing age undergoing bariatric surgery, in order to reduce their preoperative POPs load more rapidly. Indeed, the investigators hypothesize that cholestyramine is capable, outside of acute exposure accidents, of promoting the elimination and release of POPs in the human population. Given this hypothesis, a treatment administered prior to bariatric surgery could reduce pre-operative plasma levels of POPs and thus, in fine, minimize the concentrations reached post-operatively, which are dependent on the release induced by lipolysis (massive and rapid weight loss) and pre-operative plasma concentrations.

NCT ID: NCT05962372 Recruiting - Obesity Clinical Trials

Culturally Adapted Dietary Clinical Trial in PR

PRECISION
Start date: April 16, 2024
Phase: N/A
Study type: Interventional

This project will determine whether a diet culturally adapted to adults in Puerto Rico can effectively decrease cardiometabolic risk factors. This will help define a culturally-appropriate, feasible, and sustainable diet intervention aimed at reducing cardiovascular, type 2 diabetes, and obesity outcomes.

NCT ID: NCT05917132 Recruiting - Obesity, Abdominal Clinical Trials

Production of Gut Microbiota-Derived Metabolites in Response to Different Fatty Acid Profiles

METAc
Start date: June 12, 2023
Phase: N/A
Study type: Interventional

The proposed project mainly aims to investigate the microbial processes leading to dietary metabolites production, independently of long-term microbiota adaptation to the diet, by measuring the microbiota-derived metabolite production from a meal sequence rich in saturated fatty acids (SFA) or the same meals but rich in polyunsaturated fatty acids (PUFA) in individuals with or without obesity and Type 2 diabetes (T2D)

NCT ID: NCT05882149 Recruiting - Abdominal Obesity Clinical Trials

Single Strain Probiotic

CHOICE
Start date: June 22, 2023
Phase: N/A
Study type: Interventional

Probiotics have been recognized as functional foods with beneficial effects against obesity and cardiometabolic diseases, such as dyslipidemia, type 2 diabetes and the reduction of visceral fat mass, body weight and waist circumference. In previous studies, it was shown that capsule/powder probiotic or postbiotic supplementation containing a single strain probiotic, could reduce anthropometric parameters, including the visceral fat area, and contribute to type 2 diabetes management in subjects with abdominal obesity. Similar findings were found when this single strain probiotic was delivered through enriched seafood sticks. Results showed that enriched seafood sticks significantly reduced insulin concentrations and HOMA-IR, pulse pressure, waist circumference, body weight and triglycerides. These findings suggest that this specific single strain probiotic as a probiotic or postbiotic, could be a complementary strategy in the management of cardiometabolic disease risk factors. Probiotics have mostly been studied incorporated in dairy food matrix. Other food matrices, such as chewing gum, have scarcely been exploited by the food industry. Chewing gum as a novel vehicle for probiotics presents the ability to release active ingredients into the oral cavity with a steady and rapid action. Furthermore, it has a high acceptance amongst adults and children and present few side effects. No previous randomized controlled trials have examined the effect of a probiotic chewing gum on anthropometric adiposity biomarkers and glucose homeostasis in abdominally obese individuals. The main objective of the present study is to evaluate the efficacy of single strain probiotic in the reduction of waist circumference in abdominally obese individuals. The specific objectives: - To evaluate the efficacy of single strain probiotic in the improvement of other anthropometric biomarkers (waist-hip-ratio, body weight, BMI, total fat mass, visceral fat index, free fat mass, lean body mass, conicity index, visceral adipose tissue and subcutaneous fat). - To evaluate the efficacy of single strain probiotic in the management of glucose homeostasis. - To evaluate the efficacy of single strain probiotic in the management of serum lipid levels. - To evaluate the efficacy of single strain probiotic in the reduction of blood pressure and pulse pressure. - To asses Quality of life after single strain probiotic supplementation. - To identify changes in caloric intake and subjective satiety after single strain probiotic supplementation. - To identify changes in gastrointestinal health after single strain probiotic supplementation. - To identify changes in the oral microbiome after single strain probiotic supplementation. - To identify changes in the gastrointestinal microbiome after single strain probiotic supplementation.

NCT ID: NCT05879692 Recruiting - Obesity Clinical Trials

Response of Irritable Bowel Syndrome to Abdominal Fat Reduction

Start date: May 28, 2023
Phase: N/A
Study type: Interventional

The purpose of the study is to find out the response of Irritable Bowel Syndrome (IBS) to abdominal fat reduction in central obese patients using: application of High Intensity Focused Ultrasound (cavitation) on the abdominal region, aerobic exercise and a dietary regimen that will be low in calories (Low Caloric Diet) and low in fermentable oligo-, di-, mono- saccharides and polyols (low-FODMAPs).

NCT ID: NCT05874635 Recruiting - Clinical trials for Diabetes Mellitus, Type 2

Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)

Start date: May 11, 2023
Phase: N/A
Study type: Interventional

The use of continuous glucose monitoring (CGM) in earlier data has inspired behavioral changes leading to improved adherence to an exercise plan in individuals and eating habits in people with diabetes. Mobile health (mHealth) platforms provide satisfactory, easy-to-use tools to help participants in the pursuit of weight change goals. We hypothesize that the use of CGM data and the Signos mHealth platform will assist with weight control in a population of people with type 2 diabetes mellitus who are not using insulin.

NCT ID: NCT05833009 Recruiting - Schizophrenia Clinical Trials

Acupuncture Treatment for Schizophrenia-related Central Obesity

Start date: October 1, 2022
Phase: N/A
Study type: Interventional

This clinical trial aims to test the effect of acupuncture in patients with schizophrenia-related central obesity. The main question it aims to answer is: • The effect, safety, and maintenance of acupuncture on schizophrenia-related central obesity. Participants will receive acupuncture treatment on purpose acupoints, acupuncture on acupoint peripheries, or fake acupuncture treatment on purpose acupoints for 20 weeks. And they need three follow-up visits during the treatment period and two follow-up visits after treatment. Researchers will compare the waist circumstance of these three groups to see if the purpose acupoints are valid for schizophrenia-related central obesity.